Medicaid

Pharmalot

Pharmalittle: More turnover at Gilead Sciences; EMA scales back its transparency policy

By Ed Silverman

Laura Dolph
Politics

Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids

By Lev Facher

CVS/Aetna
Pharmalot

Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing

By Ed Silverman

Charlie Baker
Pharmalot

To lower state drug costs, the National Governors Association is promoting several ideas

By Ed Silverman

HHS Secretary Alex Azar
Politics

HHS takes aim at drug companies for an ‘abusive behavior’ in Medicaid

By Ike Swetlitz

Hepatitis C
Pharmalot

Louisiana explores a ‘Netflix’ subscription model for buying hepatitis C drugs

By Ed Silverman

Pharmalot

AstraZeneca to pay $110 million to Texas for defrauding Medicaid and illegally marketing drugs

By Ed Silverman

An UBER application is shown as cars drive by.
First Opinion

Curtailing Medicaid’s transportation benefit is ‘penny-wise and pound-foolish’

By Michael Adelberg, Patricia Salber, and Michael Cohen

Pharmalot

Pharmalittle: CVS and Ohio battle over Medicaid data; AbbVie strikes another Humira biosimilar deal

By Ed Silverman

Pharmalot

Pharmalittle: CMS drops plan for Novartis drug; lawsuit offers fresh details on Purdue opioid marketing

By Ed Silverman

Pharmalot

Pharmalittle: Takeda bid for Shire passes first shareholder test; Amazon agrees to buy PillPack

By Ed Silverman

Generic medication
Politics

Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates

By Erin Mershon

Sarepta - hearing
Politics

Medicaid must pay for drugs approved through FDA’s ‘accelerated’ pathway, agency tells states

By Ike Swetlitz

Medicaid
Pharmalot

Ohio peels back the curtain on a lucrative PBM profit center

By Ed Silverman

Hospital medicaid
First Opinion

An insider’s view of the myths and misconceptions behind 340B ‘reform’

By Bradford R. Lang

Prison
Pharmalot

Can a federal drug discount program unlock savings for state prisons?

By Ed Silverman

Seema Verma
Politics

Which drug makers’ medicines are racking up bigger and bigger bills for Medicare and Medicaid?

By Erin Mershon

Rep. Peter Welch
Pharmalot

Lawmakers introduce bill to fine drug makers for incorrect Medicaid classifications

By Ed Silverman

Boston Children’s Hospital
First Opinion

Medicaid’s unnecessary barriers delay care for children with complex needs

By Nick Manetto, Joshua Greenberg, and Mathieu Gaulin

Amazon Berkshire JPM Health Care
Business

Bill Gates is glad Amazon is getting into health care — but cautions it’s complicated

By Megan Thielking

Pharmalot

Pharmalittle: Has ‘right to try’ legislation stalled? Probes into copay charities are slowing contributions

By Ed Silverman

Vertex Pharmaceuticals Inc. building
Pharmalot

New York panel votes to lower the cost of a pricey Vertex drug for cystic fibrosis

By Ed Silverman

Pharmalot
Pharmalot

How a patient advocacy group is used to promote an Insys drug and other fentanyl meds

By Ed Silverman

Vertex
Pharmalot

New York panel to review Vertex pricing in first test of new law

By Ed Silverman

Pill pack
Business

Feds broaden the definition of ‘pharmacy’ in a bid to level playing field for startups

By Casey Ross

Generics
Pharmalot

To boost generic competition, analysis says, FDA should approve drugs OK’d by foreign regulators

By Ed Silverman

Patient data and tech
Business

The government wants to free your health data. Will that unleash innovation?

By Casey Ross

Generic medication
Pharmalot

Vermont transparency pricing law may show big price hikes, but disappoints lawmakers

By Ed Silverman

Vertex
Pharmalot

Vertex battles with the U.K. over the price of its cystic fibrosis drug

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy